摘要
目的探讨通心络胶囊对经皮冠状动脉（冠脉）介入治疗（PCI）后患者的影响。方法将80例PCI患者按随机原则分为两组。对照组（38例）术后使用B受体阻滞剂、他汀类、硝酸酯类药物；试验组（42例）在对照组用药基础上加服通心络胶囊0．52g，每日3次。两组均连用6个月。随访6个月，观察6个月内急性心肌梗死（AMI）、心绞痛、心源性休克、冠脉再狭窄等并发症的发生率及血常规、血脂及肝肾功能的变化。结果对照组发生AMI2例（5．3％），心绞痛8例（21．1％），冠脉再狭窄3例（7．9％），无心源性休克；试验组4个并发症发生例数均为0，两组差异显著（P〈0．05或P〈0．01）。试验组治疗后1、3和6个月总胆固醇（Tc）、低密度脂蛋白胆固醇（LDL—C）水平均较治疗前及对照组显著降低（均P〈0．01）；治疗3个月、6个月三酰甘油（TG）较治疗前及对照组明显降低（均P〈0．05）。两组治疗后高密度脂蛋白胆固醇（HDL—C）有逐渐升高趋势，血小板计数（PLT）有轻度降低，但差异均无统计学意义（均P〉0．05）。两组治疗前后肝肾功能无明显改变（均P〉0．05）。结论使用通心络胶囊对PCI患者疗效显著，副作用小。
Objective To analyze the effect of Tongxinluo capsules （通心络胶囊） on patients after percutaneous coronary intervention （PCI）. Methods Patients who underwent PCI were randomly divided into two groups： control and Tongxinluo groups. The control group （n=38） was treated with β-blockers, tatins, nitrates; Tongxinluo group （n=42） was treated with the similar western drugs in the control group and Tongxinluo capsules, 0.52 g once and three times a day. The two groups were treated consecutively for 6 months. During the 6 months of follow-up, the rate of complications, such as acute myocardial infarction （AMI）, angina pectoris, cardiogenic shock, coronary restenosis, and the changes of the blood routine, hepatic and renal functions and blood lipids were observed. Results In the control group, 2 cases of AMI （5.3%）, 8 cases of angina pectoris （21.1%）, 0 case of cardiogenic shock, 3 cases of restenosis （7.9%） occurred. In the Tongxinluo group, no above complication developed （P〈0.05 or P〈0.01）. In the Tongxinluo group, after the 1st, 3rd and 6th month of treatment the total cholesterol （TC） and low density lipoprotein-cholesterol （LDL-C） levels were lower than those before the treatment and in the control group （all P〈0.01）, and after the 3rd month and 6th month of treatment, the triglyceride （TG） level was obviously lower than that before the treatment and in the control group （all P〈0. 05）; after the treatment, the level of high density lipoprotein （HDL-C） was gradually heightened, and the blood platelet level reduced mildly, but there were no significant differences between the two groups （all P〈0.05）. In the two groups, after treatment there were no marked changes in hepatic and renal functions （all P〈0.05）. Conclusion Tongxinluo capsules are obviously effective on patients having been treated with PCI.
出处
《中国中西医结合急救杂志》
CAS
北大核心
2010年第3期175-176,共2页
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
基金
河北省沧州市科技局课题资助项目（082D16）
关键词
通心络胶囊
心肌梗死
经皮冠状动脉介入治疗
Tongxinluo capsule
Myocardial infarction
Percutaneous coronary intervention
